BOB1-derived peptide APAPTAVVL presented by HLA-B*07:02 (BOB1/HLA-B*07:02)

The BOB1-derived peptide APAPTAVVL presented by HLA-B*07:02 is a specific peptide-major histocompatibility complex (pMHC) that serves as a target for immunotherapy in B-cell malignancies. BOB1, also known as POU2AF1 or OBF-1, is a transcriptional coactivator essential for B-cell response and germinal center formation, and it is highly and consistently expressed in multiple myeloma and various B-cell lymphomas (Jahn et al., 2015, Blood). The specific nonamer peptide APAPTAVVL is processed from the BOB1 protein and presented on the cell surface by the HLA-B*07:02 allele, making it a highly specific target for T-cell receptor (TCR) based therapies. Because BOB1 expression is largely restricted to the B-cell lineage, targeting this complex allows for the selective destruction of malignant B-cells while sparing most non-hematopoietic tissues. Therapeutic strategies focusing on this target include the development of TCR-engineered T-cells (TCR-T) designed to recognize the APAPTAVVL/HLA-B*07:02 complex with high affinity and specificity (Schub et al., 2009, Blood). This target is particularly relevant for patients with multiple myeloma who carry the HLA-B*07:02 allele, providing a personalized approach to cellular immunotherapy.

Other names

POU2AF1-derived peptide APAPTAVVL presented by HLA-B*07:02BOB.1/HLA-B7 complexB-cell-specific coactivator OBF-1 peptide-MHC complexAPAPTAVVL-HLA-B*07:02

T-cell receptor (TCR) mediated recognition of the peptide-HLA complex on the surface of malignant B-cells, leading to the activation of cytotoxic T-lymphocytes and subsequent lysis of the target tumor cell.